UK Markets closed

STADA Arzneimittel Aktiengesellschaft (0OM4.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
93.50+2.50 (+2.75%)
At close: 5:00PM BST

STADA Arzneimittel Aktiengesellschaft

Stadastrasse 2-18
Bad Vilbel 61118
49 6101 603 0

Full-time employees12,339

Key executives

NameTitlePayExercisedYear born
Mr. Peter GoldschmidtChairman of the Exec. Board & CEO1.25MN/A1964
Mr. Miguel Pagan FernandezCTO & Member of Exec. Board584kN/A1965
Dr. Wolfgang OlligGroup Chief Financial Officer & Member of Exec. BoardN/AN/AN/A
Dr. Christoph DenglerExec. VP of Global LegalN/AN/AN/A
Mr. Frank StaudExec. VP of Global Communications & BrandingN/AN/AN/A
Ms. Simone BergerExec. VP of Global HRN/AN/A1979
Mr. Carsten CronExec. VP of Emerging MarketsN/AN/AN/A
Mr. Eelco OckersExec. VP of GermanyN/AN/AN/A
Mr. Roger Scarlett-SmithExec. VP UK & USN/AN/A1960
Dr. Steffen WagnerExec. VP of European MarketsN/AN/AN/A
Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


STADA Arzneimittel Aktiengesellschaft engages in the health care and pharmaceuticals business worldwide. The company operates in two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxon for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; and Omeprazol and Pantoprazol for gastric ulcer/reflux. The Branded Products segment offers Bortezomib STADA for cancer; APO-Go for Parkinson's disease; Grippostad for cold; Zoflora for disinfections; and Snup for head cold. The company serves doctors, pharmacists, patients, health insurance organizations, buying groups, pharmacy chains, and wholesalers or mail-order companies. It has strategic partnership with XBrane Biopharma for the development of biosimilars; and Alvotech ehf for the marketing of biosimilars. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare GmbH.

Corporate governance

STADA Arzneimittel Aktiengesellschaft’s ISS governance QualityScore as of 1 November 2019 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.